On April 26, 2018 Vaccibody AS, a clinical-stage company focused on developing cancer vaccines to target solid tumors, reported clinical data demonstrating vaccine-induced killer T cell responses (CD8+) in patients in their clinical program to treat precancerous cervical intraepithelial neoplasia (CIN) 2/3 lesions (VB C-01) (Press release, Vaccibody, APR 26, 2018, View Source [SID1234525755]). President and Chief Scientific Officer, Agnete Fredriksen, will present the data at the European Neoantigen Summit this week.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The phase IIa part of Vaccibody´s VB C-01 study with VB10.16 immunotherapy was fully recruited in December 2017. We here report immunogenicity data for the first 10 patients in phase IIa, showing vaccine-induced immune responses in 10 out of 10 vaccinated patients. In total, 26 patients in the phase I/IIa study have now been tested of which 25 (96 %) elicited an increased immune response after vaccination.
Further analysis in selected patients detected both killer T cells (CD8+) and helper T cell responses (CD4+) in vaccinated patients ex vivo, and both cell types produced proinflammatory cytokines. Strong CD8+ T cell responses were verified by multimer analysis. These data confirm in a clinical setting the unique ability of the Vaccibody DNA vaccine platform to induce strong killer T cell responses.
Agnete Fredriksen, President & Chief Scientific Officer of Vaccibody said, "We are very pleased that we now can present data showing activation of CD8+ killer T cell responses in patients vaccinated with our lead compound VB10.16. The new clinical immunogenicity data clearly demonstrates the ability of the Vaccibody vaccine technology to elicit strong immune responses, as we observed increased immune response in 25 out of the 26 vaccinated patients analysed so far. We know that CD8+ T cell have the potential to directly kill cancer cells and we look forward to study this further. With these promising immunogenicity data from the HPV trial in combination with the unique responses dominated by CD8+ T cells observed in our preclinical neoantigen studies, we are also eager to follow the responses in the neoantigen clinical trial, which has already recruited its first patient".